| Plan Category | (a) Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights | (b) Weighted- Average Exercise Price of Outstanding Options, Warrants and Rights | (c) Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column(a)) | |||||||||
| Equity compensation plans approved by security holders | ||||||||||||
| 2023 Equity Incentive Plan(1) | 2,322,098 | $ | 8.14 | 2,293,816 | ||||||||
| 2021 Equity Incentive Plan(2) | 93,642 | $ | 12.72 | - | ||||||||
| 2023 Employee Stock Purchase Plan(3) | - | $ | - | 238,600 | ||||||||
| Equity compensation plans not approved by security holders | - | $ | - | - | ||||||||
| Total | 2,415,740 | $ | 8.32 | 2,532,416 | ||||||||
| Name | Fees Paid or Earned in Cash ($) | Stock Awards ($) | Option Awards ($) | Non-Equity Incentive Plan Compensation ($) | Nonqualified Deferred Compensation Earnings ($) | All Other Compensation ($) | Total ($) | |||||||||||||||||||||
| Bernard Davitian (1) | $ | 6,413 | $ | - | $ | - | $ | - | $ | - | $ | - | $ | 6,413 | ||||||||||||||
| Mette Kirstine Agger | 10,501 | - | - | - | - | - | 10,501 | |||||||||||||||||||||
| Steven Altschuler, M.D. | 139,221 | - | 60,933 | - | - | - | 200,153 | |||||||||||||||||||||
| Reinaldo Diaz | 7,375 | - | - | - | - | - | 7,375 | |||||||||||||||||||||
| Brenda Cooperstone, M.D. | 18,908 | - | 493,103 | - | - | 17,125 | 529,135 | |||||||||||||||||||||
| Paula HJ Cholmondeley | 42,050 | - | 364,556 | - | - | - | 406,606 | |||||||||||||||||||||
| (1) Compensation awarded to Mr. Davitian was paid directly to Omega Fund, where Mr. Davitian serves as a partner. | ||||||||||||||||||||||||||||
| Name and Principal Position | Year | Salary ($) | Bonus ($) | Stock Awards ($) | Option Awards(1) ($) | Non-Equity Incentive Plan Compensation ($) | All Other Compensation(2) ($) | Total ($) | ||||||||||||||||||||||
| R. Nolan Townsend | 2023 | 508,000 | 872,883 | 347,880 | 8,455 | 1,737,218 | ||||||||||||||||||||||||
| Chief Executive Officer and Director | 2022 | 465,000 | - | 186,000 | 54,432 | 705,432 | ||||||||||||||||||||||||
| Jenny R. Robertson, J.D. | 2023 | 402,500 | 678,734 | 204,000 | 11,400 | 1,296,634 | ||||||||||||||||||||||||
| Chief Business and Legal Officer | 2022 | 257,813 | 99,000 | 690,997 | 14,850 | 2,588 | 1,065,248 | |||||||||||||||||||||||
| Eric Adler, M.D. | 2023 | 296,500 | 234,750 | (3) | 2,419,424 | 80,750 | 11,400 | 3,042,824 | ||||||||||||||||||||||
| Chief Medical Officer and Head of Research | ||||||||||||||||||||||||||||||
| Micah Zajic | 2023 | 423,229 | 166,000 | (4) | 2,464,231 | (5) | 11,096 | 3,064,556 | ||||||||||||||||||||||
| Former Chief Financial Officer | ||||||||||||||||||||||||||||||
